Clinical Data
BRAFTOVI™ (encorafenib) + MEKTOVI® (binimetinib) Receives Positive CHMP Opinion for Advanced BRAF-mutant Melanoma
Array BioPharma
PR-M08-18-NI-010Aug 02, 2018
Positive Opinion
Pierre Fabre receives positive CHMP opinion for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in adult patients with advanced BRAF-mutant melanoma
Pierre Fabre
PR-M08-18-NI-008Aug 02, 2018
Positive Opinion
Janssen Receives Positive CHMP Opinion for Darzalex®▼ (daratumumab) as Frontline Treatment for Newly Diagnosed Patients with Multiple Myeloma
Janssen Pharmaceutical Companies
PR-M08-18-NI-007Aug 02, 2018
Biosimilar
Mylan and Fujifilm Kyowa Kirin Biologics Announce Positive CHMP Opinion for Hulio™, Biosimilar Adalimumab
Mylan
PR-M08-18-NI-001Aug 01, 2018